SLC5A2 and chronic kidney disease: Indeed, several animal studies showed that treatment with SGLT2 inhibitors led to increased plasma renin activity in both diabetic mice (Woods et al., 2019) and nondiabetic CKD rats (Li et al., 2018a), whereas other studies observed no such change (Shin et al., 2016).